Benefiting patients worldwide, funding accelerates chronic lymphocytic leukemia research and

使全球患者受益，资金加速了慢性淋巴细胞白血病的研究和

rare cancer drug development through the Oxford-Harrington Rare Disease Centre and UH

通过牛津-哈灵顿罕见病中心和UH进行罕见癌症药物开发

Seidman Cancer Center

塞德曼癌症中心

CLEVELAND and OXFORD, England

克利夫兰和英国牛津

,

，

May 6, 2026

2026年5月6日

/PRNewswire/ --

/PRNewswire/ --

University Hospitals

大学医院

(UH) has received $12.5 million in transformational support from Dee and Jimmy Haslam to fuel research and drug development for chronic lymphocytic leukemia (CLL) and other rare blood cancers through the Oxford-Harrington Rare Disease Centre and University Hospitals Seidman Cancer Center.

(UH) 已获得 Dee 和 Jimmy Haslam 提供的 1250 万美元的转型支持，用于通过牛津-哈林顿罕见病中心和大学医院塞德曼癌症中心推动慢性淋巴细胞白血病 (CLL) 以及其他罕见血液癌症的研究和药物开发。

The Haslams, managing partners of Haslam Sports Group and owners of the Cleveland Browns, were inspired by UH's proven, philanthropy‑fueled approach to drug development established by Harrington Discovery Institute at UH as well as its unique partnership with the University of Oxford. The Haslams' newest commitment includes $10 million to accelerate research and drug development focused on CLL and related blood cancers via the Oxford-Harrington Rare Disease Centre, which is dedicated to creating breakthrough medicines for rare conditions with limited or no existing therapies.

哈斯拉姆家族是哈斯拉姆体育集团的管理合伙人，同时也是克利夫兰布朗队的拥有者，他们受到大学医院（UH）通过哈林顿发现研究所建立的经过验证的、以慈善为驱动的药物开发方法，以及其与牛津大学独特合作关系的启发。哈斯拉姆家族最新的承诺包括捐赠1000万美元，用于通过牛津-哈林顿罕见病中心加速针对慢性淋巴细胞白血病（CLL）及相关血液癌症的研究和药物开发，该中心致力于为治疗选择有限或尚无治疗方法的罕见疾病开发突破性药物。

An additional $2.5 million will benefit UH Seidman Cancer Center, establishing an endowed chair in CLL research as well as an innovation fund to drive advancements in care..

额外的 250 万美元将使 UH 塞德曼癌症中心受益，用于设立 CLL 研究的捐赠主席职位以及推动护理进步的创新基金。

'I am extremely grateful that I am living a full, healthy life after being diagnosed with CLL in 2021,' said Dee Haslam. 'This gift to University Hospitals is an investment into research and drug development. Together with UH Seidman Cancer Center and the Oxford-Harrington Centre, we hope to increase knowledge of CLL, generate new treatments and give others the confidence and information they need to navigate the disease.

“在2021年被诊断出患有CLL后，我过着充实而健康的生活，对此我深感感激，”迪·哈斯拉姆说道。“这份给大学医院的礼物是对研究和药物开发的投资。我们希望与UH塞德曼癌症中心和牛津-哈林顿中心一起，增进对CLL的了解，研发新的治疗方法，并给予其他人应对这种疾病所需的信心和信息。”

Ideally, cures for other blood disorders will be discovered in the process. We are humbled to help push progress forward and have such an outstanding medical institution like University Hospitals in Northeast Ohio.'.

理想情况下，在这个过程中还会发现其他血液疾病的治疗方法。我们很谦逊地推动这一进展，并且在俄亥俄州东北部有像大学医院这样优秀的医疗机构。

CLL is the most common form of leukemia in adults and modern targeted therapies have transformed it into a manageable, chronic condition. However, CLL remains a rare disease with no cure. Scientists working with the Oxford-Harrington Rare Disease Centre and UH Seidman Cancer Center hope to change that by advancing new therapeutics into clinical trials toward a goal of curing the disease..

慢性淋巴细胞白血病是成人中最常见的白血病类型，现代靶向疗法已将其转变为一种可控制的慢性疾病。然而，慢性淋巴细胞白血病仍然是一种无法治愈的罕见病。在牛津-哈林顿罕见病中心和UH塞德曼癌症中心工作的科学家们希望通过推进新疗法进入临床试验，朝着治愈该疾病的目标迈进，希望改变这一现状。

'We are very grateful to Dee and Jimmy for this extraordinary investment and for the confidence it represents in our mission,' said Jonathan Stamler, MD, President and Co‑Founder of Harrington Discovery Institute, Distinguished University Professor, Robert S. and Sylvia K. Reitman Family Foundation Chair of Cardiovascular Innovation, University Hospitals and Case Western Reserve University.

“我们非常感谢Dee和Jimmy的这项非凡投资，以及它对我们使命所代表的信任，”Harrington Discovery Institute院长兼联合创始人、杰出大学教授、Robert S. and Sylvia K. Reitman家庭基金会心血管创新主席、大学医院和凯斯西储大学的Jonathan Stamler医学博士说道。

'Their generosity creates a remarkable opportunity to advance a next generation of medicines for blood cancers, and we are committed to ensuring their gift has palpable impact on the lives of patients in need.'.

“他们的慷慨为推动下一代血癌药物的发展创造了非凡的机会，我们致力于确保他们的馈赠对有需要的患者生活产生切实的影响。”

Since its founding in 2012, Harrington Discovery Institute has advanced cures on a global scale with 227 medicines in the making, 75 institutions supported, 47 companies launched, 24 medicines in the clinic and 15 licenses to pharma.

自2012年成立以来，哈林顿发现研究所已经在全球范围内推动了227种药物的研发，支持了75家机构，创立了47家公司，已有24种药物进入临床阶段，并向制药行业发放了15个许可证。

'Rare diseases, and rare cancers in particular, represent one of the greatest areas of unmet medical need worldwide,' said David Cameron, former Prime Minister of the U.K. and Chair of the Oxford‑Harrington Rare Disease Centre Advisory Council. 'I am delighted to see this generous support, which can help unlock meaningful advances in areas long overlooked and urgently in need of attention.

“罕见疾病，尤其是罕见癌症，是全球范围内未满足医疗需求最大的领域之一，”英国前首相、牛津-哈灵顿罕见病中心顾问委员会主席戴维·卡梅伦表示。“我非常高兴看到如此慷慨的支持，这将有助于在长期被忽视且迫切需要关注的领域取得有意义的进展。”

This investment highlights the importance of international collaboration in accelerating progress for people affected by rare conditions.'.

这项投资突显了国际合作在加速为受罕见疾病影响的人群取得进展方面的重要性。

'We are grateful to the Haslams for being devout supporters of University Hospitals and our mission for many years,' said

“我们非常感谢哈斯拉姆家族多年来一直虔诚地支持大学医院及我们的使命，”

Cliff A. Megerian, MD, FACS,

克利夫·A·梅格里安，医学博士，FACS，

University Hospitals CEO and Jane and Henry Meyer Chief Executive Officer Distinguished Chair. 'One of our health system's guiding principles is 'the most needy are the most worthy,' and that is especially the case for those impacted by rare diseases. It's important we give them hope, and we look forward to doing so through drug development with our unique infrastructure.'.

大学医院首席执行官，简和亨利·迈耶首席执行官杰出主席。“我们卫生系统的一个指导原则是‘最需要帮助的人是最值得的’，这对那些受罕见病影响的人来说尤其如此。重要的是我们要给他们希望，我们期待通过我们独特的基础设施进行药物开发来实现这一目标。”

Theodoros Teknos, MD,

西奥多罗斯·特克诺斯，医学博士，

President & Scientific Director of UH Seidman Cancer Center and the Jane and Lee Seidman Chair in Cancer Innovation, said: 'The Haslams' support reflects their commitment to the health and well-being of the Cleveland community. Identifying new treatment options and continuing to work towards finding a cure for cancer is something our researchers work towards each and every day.

UH塞德曼癌症中心总裁兼科学总监、简和李·塞德曼癌症创新主席表示：“哈斯拉姆家族的支持体现了他们对克利夫兰社区健康与福祉的承诺。我们的研究人员每天都在努力寻找新的治疗方案，并继续朝着治愈癌症的目标迈进。”

Their funding will support an endowed chair position so that we can continue making progress in the field of cancer research.'.

他们的资金将支持一个捐赠的主席职位，以便我们能够继续在癌症研究领域取得进展。

Fewer than five percent of rare diseases currently have an approved therapy, representing a significant unmet medical need worldwide. The Oxford-Harrington Centre addresses this gap by funding and supporting scholars across the U.S., U.K., and Canada, with the goal of creating new medicines for patients who have limited or no treatment options..

目前，只有不到百分之五的罕见病拥有获批的疗法，这代表着全球范围内存在显著未满足的医疗需求。牛津-哈灵顿中心通过资助和支持美国、英国和加拿大的学者来填补这一空白，旨在为那些治疗选择有限或无治疗方案的患者开发新药。

The Haslams have a known passion for health and discovery. The UH Haslam Sports Innovation Center opened in 2023 as a catalyst to improve performance, reduce injury risk and promote healing for stronger, healthier athletes. The center was developed thanks to a visionary $20 million leadership commitment from the Haslams, with the goal of identifying, supporting and investing in the world's best sports medicine innovations..

哈斯拉姆家族对健康和探索有着众所周知的热情。UH 哈斯拉姆体育创新中心于2023年开放，旨在促进运动员表现、降低受伤风险并促进康复，培养更强壮、更健康的运动员。该中心得益于哈斯拉姆家族富有远见的2000万美元领导力承诺而建立，目标是识别、支持和投资全球最佳的运动医学创新。

Elected in 2015, Dee Haslam is a dedicated and active member of the UH Board of Directors and is co-chair of

2015年当选的迪·哈斯拉姆是UH董事会的敬业且活跃的成员，并且是联合主席之一。

Because of You: The Campaign for University Hospitals

因为有你：大学医院的筹款活动

,

，

UH's $2 billion fundraising campaign.

夏威夷大学的20亿美元筹款活动。

SOURCE Harrington Discovery Institute

来源：哈林顿发现研究所

21

21

%

%

more press release views with

更多新闻发布观点

Request a Demo

请求演示